Page last updated: 6 June 2017
Drug Utilisation Sub Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) assesses estimates on projected usage and financial cost for medicines.
It also collects and analyses data on actual use (including in comparison with different countries), and provides advice to PBAC.
DUSC contact details can be found in PBS Contacts
The DUSC Outcome Statements provide a high level summary of the topics discussed at each DUSC meeting. This includes summarised results and DUSC’s views on the utilisation analyses of PBS medicines and therapeutic areas (multiple medicines in a treatment area) considered at that meeting. The Outcome Statement also provides notice of the PBS medicines and therapeutic areas selected for consideration at future DUSC meetings.
The DUSC Utilisation Analysis Public Release Documents provide public access to the DUSC utilisation analysis reports. The DUSC considers the reports will assist stakeholders including consumers, health professionals, researchers and pharmaceutical sponsors, to better understand how PBS medicines are currently being used, the methods DUSC employs to analyse utilisation of PBS medicines and the PBS data available for these analyses. The reports may also outline how the current utilisation of PBS medicines compares with the use as recommended by the PBAC.
The DUSC considers the publication of the DUSC Outcome Statements and Utilisation Analysis Public Release Documents provide greater transparency of the working of the DUSC and the utilisation of PBS medicines. The DUSC considers that the publications uphold the National Medicines Policy, which states that consumers and health practitioners should be encouraged to understand the costs, benefits and risks of medicines.
A/Professor Christopher Etherton-Beer (Chair) is a professor of Geriatric Medicine at the University of Western Australia and a Consultant Physician of Geriatric Medicine at the Royal Perth Hospital. He is also a member of the PBAC.
Dr Kylie Easton is a pharmacist and is currently employed as the Formative Research Manager at NPS MedicineWise.
Professor Catherine Hill is a specialist rheumatologist and an epidemiologist at the Queen Elizabeth and Royal Adelaide Hospitals in Adelaide. She is also a member of the PBAC.
Dr Anna Kemp-Casey is a research academic specialising in pharmacoepidemiology and the impact of national health policy on medicines use. She is currently a Senior Research Fellow with the Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia and The Centre for Health Services Research, The University of Western Australia.
Dr Tracey Laba is a Research Fellow at The George Institute for Global Health specialising in health economics. Her main area of research interest is medications adherence.
Professor Sallie Pearson is a research academic at the Centre for Big Data Research in Health at the University of New South Wales.
Ms Jan Donovan is a consumer advocate with experience on a number of committees in health, ageing and pharmaceutical policy.
Professor Libby Roughead is a research professor with expertise in pharmacy, pharmacoepidemiology and quality use of medicines at the Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia.
Professor Debra Rowett is a clinical pharmacist and Director of the Drug and Therapeutics Information Service at the Repatriation General Hospital, South Australia.
Dr Rashmi Sharma is a practising general practitioner and Practice Principal of a large multidisciplinary teaching practice in Canberra. She holds an Adjunct Associate Professor title at the ANU Medical School. She is also a medical educator and contributes to a number of Commonwealth and local committees related to health.
Professor Andrew Wilson is the Chair of the PBAC. He has specialist professional qualifications in clinical medicine and public health medicine and a PhD in epidemiology.
Ms Elizabeth DeSomer is the industry member nominated by Medicines Australia.
Ms Belinda Wood is the industry member nominated by the Generic and Biosimilar Medicines Association.